Fang-Shu Ou
ScholarGPS® ID: 24226193162612
Affiliation History
Discipline
Statistics
Top Specialties
Cancer | Colorectal Cancer | Chemotherapy | Neoplasm | Bevacizumab | Biomarker | Mathematical Optimization | DNA | Adjuvant Therapy | Leukemia | Pancreas
Metrics Summary
Publication Count
105
Predicted Citations
2,605
Predicted h-index
28
Ranking
Publications and Citation History
Publications based on Top Specialties
Types of Publication
- Publications
- Books
- Patents
- NIH/NSF
Add
Delete
|
---|
Evaluating the utility of ZNF331 promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance) (journal article) Epigenetics, volume 19, issue 1 (2024). |
Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 3588-3588 (2024). |
Journal of Clinical Oncology, volume 42, issue 16_suppl, pages 3144-3144 (2024). |
Prognostication of ß-catenin ( CTNNB1) in patients with HCC treated with first line immunotherapy. (journal article) Journal of Clinical Oncology, volume 42, issue 16_suppl, pages e15146-e15146 (2024). |
HER2 Gene Expression Levels Are Predictive and Prognostic in Patients With Metastatic Colorectal Cancer Enrolled in CALGB/SWOG 80405 (journal article) Journal of Clinical Oncology, volume 42, issue 16, pages 1890-1902 (2024). |
DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations (journal article) Journal of Clinical Oncology, volume 42, issue 4, pages 399-409 (2024). |
Utilizing quantitative pathologic analysis of digitized images of rectal cancer (RC) to predict response to neoadjuvant therapy (NAT). (journal article) Journal of Clinical Oncology, volume 42, issue 3_suppl, pages 200-200 (2024). |
108P FGFR2 fusions and their impact on efficacy of standard chemotherapy in patients with biliary tract cancer (journal article) Annals of Oncology, volume 34 (2023). |
Changes in Prescribing Patterns in Stage III Colon Cancer (journal article) Journal of the National Comprehensive Cancer Network, volume 21, issue 8, pages 841-850.e4 (2023). |
Journal of Clinical Oncology, volume 41, issue 16_suppl, pages 3533-3533 (2023). |
Journal of the National Comprehensive Cancer Network, volume 21, issue 3.5, pages CLO23-030- (2023). |
A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations. (journal article) Journal of Clinical Oncology, volume 41, issue 4_suppl, pages 139-139 (2023). |
Journal of Clinical Oncology, volume 41, issue 3, pages 472-478 (2023). |
International Journal of Cancer, volume 152, issue 2, pages 123-136 (2023). |
Epigenetics, volume 17, issue 12, pages 1715-1725 (2022). |
ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer (journal article) Nature Communications, volume 13, issue 1 (2022). |
329P Duration of adjuvant therapy in stage III colon cancer: A real world multi-institutional US-based experience (journal article) Annals of Oncology, volume 33 (2022). |
Current Epidemiology Reports, volume 9, issue 3, pages 183-189 (2022). |
Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance) (journal article) The Oncologist, volume 27, issue 6, pages e494-e505 (2022). |
Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance). (journal article) Journal of Clinical Oncology, volume 40, issue 16_suppl, pages 3553-3553 (2022). |